Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Show more...
FAQ
Fennec Pharmaceuticals 的股票代码是什么?▼
根据交易所不同,股票代码可能会有所不同。例如,在 交易所,Fennec Pharmaceuticals 的股票以代码 ADH 进行交易。
Fennec Pharmaceuticals 的股价在上涨吗?▼
ADH 股票较上周上涨 +0%,本月上涨 +0%,过去一年 Fennec Pharmaceuticals 上涨 +23.83%。
Fennec Pharmaceuticals 会发放股息吗?▼
是的,ADH 的股息每 年度 发放一次。每股最新股息为 0.03 USD。截至今日,股息率(FWD)% 为 0%。
Fennec Pharmaceuticals 有多少名员工?▼
截至四月 01, 2026,公司共有36名员工。
Fennec Pharmaceuticals 属于哪个行业?▼
Fennec Pharmaceuticals从事于Health Care行业。
Fennec Pharmaceuticals 何时完成拆股?▼
Fennec Pharmaceuticals 最近没有进行任何拆股。
Fennec Pharmaceuticals 的总部在哪里?▼
Fennec Pharmaceuticals 的总部位于 CA 的 Research Triangle Park。